| Subsidiaries With Non-controlling Interest |
The Stevanato Group comprises the following subsidiaries with material non-controlling interest:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, |
|
|
At December 31, |
|
Name |
|
Country |
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
Ompi of Japan Co., Ltd. |
|
Japan |
|
|
49 |
% |
|
|
49 |
% |
Medical Glass a.s. |
|
Slovakia |
|
|
0.26 |
% |
|
|
0.26 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, |
|
|
At December 31, |
|
(EUR thousand) |
|
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
Proportion of equity interest held by non-controlling interests: |
|
|
|
|
|
|
|
|
Ompi of Japan Co., Ltd. |
|
|
|
|
419 |
|
|
|
487 |
|
Medical Glass a.s. |
|
|
|
|
(56 |
) |
|
|
(48 |
) |
|
|
|
|
|
363 |
|
|
|
439 |
|
|
|
|
|
|
|
|
|
|
Profit allocated to material non-controlling interest: |
|
|
|
|
|
|
|
|
Ompi of Japan Co., Ltd. |
|
|
|
|
60 |
|
|
|
(76 |
) |
Medical Glass a.s. |
|
|
|
|
(8 |
) |
|
|
(8 |
) |
|
|
|
|
|
52 |
|
|
|
(84 |
) |
|
| Summarized Income Statement |
The tables below show the summarized income statement for the year ended December 31, 2021:
|
|
|
|
|
|
|
|
|
(EUR thousand) |
|
Ompi of Japan
Co., Ltd. |
|
|
Medical Glass a.s. |
|
|
|
|
|
|
|
|
Net Sales |
|
|
4,325 |
|
|
|
41,643 |
|
Cost of Sales |
|
|
3,542 |
|
|
|
34,425 |
|
Gross Profit |
|
|
783 |
|
|
|
7,218 |
|
|
|
|
|
|
|
|
Other operating income |
|
|
— |
|
|
|
195 |
|
Selling and marketing expenses |
|
|
299 |
|
|
|
177 |
|
Research and development expenses |
|
|
150 |
|
|
|
— |
|
General and administrative expenses |
|
|
452 |
|
|
|
3,302 |
|
Operating profit |
|
|
(118 |
) |
|
|
3,934 |
|
|
|
|
|
|
|
|
Interest income |
|
|
37 |
|
|
|
111 |
|
Interest expense |
|
|
90 |
|
|
|
42 |
|
Profit before tax |
|
|
(171 |
) |
|
|
4,003 |
|
|
|
|
|
|
|
|
Income taxes |
|
|
(48 |
) |
|
|
826 |
|
Net Profit |
|
|
(123 |
) |
|
|
3,177 |
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
(123 |
) |
|
|
3,165 |
|
|
|
|
|
|
|
|
Attributable to non-controlling interests |
|
|
(60 |
) |
|
|
8 |
|
Dividends paid to non-controlling interests |
|
|
— |
|
|
|
— |
|
The tables below show the summarized income statement for the year ended December 31, 2020:
|
|
|
|
|
|
|
|
|
(EUR thousand) |
|
Ompi of Japan
Co., Ltd. |
|
|
Medical Glass a.s. |
|
|
|
|
|
|
|
|
Net Sales |
|
|
6,811 |
|
|
|
36,852 |
|
Cost of Sales |
|
|
5,509 |
|
|
|
30,039 |
|
Gross Profit |
|
|
1,302 |
|
|
|
6,813 |
|
|
|
|
|
|
|
|
Other operating income |
|
|
— |
|
|
|
43 |
|
Selling and marketing expenses |
|
|
349 |
|
|
|
165 |
|
Research and development expenses |
|
|
157 |
|
|
|
— |
|
General and administrative expenses |
|
|
518 |
|
|
|
2,715 |
|
Operating profit |
|
|
278 |
|
|
|
3,976 |
|
|
|
|
|
|
|
|
Interest income |
|
|
17 |
|
|
|
2 |
|
Interest expense |
|
|
74 |
|
|
|
30 |
|
Profit before tax |
|
|
221 |
|
|
|
3,948 |
|
|
|
|
|
|
|
|
Income taxes |
|
|
66 |
|
|
|
834 |
|
Net Profit |
|
|
155 |
|
|
|
3,114 |
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
155 |
|
|
|
3,111 |
|
|
|
|
|
|
|
|
Attributable to non-controlling interests |
|
|
76 |
|
|
|
8 |
|
Dividends paid to non-controlling interests |
|
|
— |
|
|
|
— |
|
The tables below show the summarized income statement for the year ended December 31, 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
(EUR thousand) |
|
Ompi of Japan
Co., Ltd. |
|
|
Medirio SA |
|
|
Medical Glass a.s. |
|
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
|
2,533 |
|
|
|
— |
|
|
|
32,811 |
|
Cost of Sales |
|
|
2,207 |
|
|
|
— |
|
|
|
27,661 |
|
Gross Profit |
|
|
326 |
|
|
|
— |
|
|
|
5,150 |
|
|
|
|
|
|
|
|
|
|
|
Other operating income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Selling and marketing expenses |
|
|
451 |
|
|
|
— |
|
|
|
123 |
|
Research and development expenses |
|
|
156 |
|
|
|
1,013 |
|
|
|
— |
|
General and administrative expenses |
|
|
437 |
|
|
|
25 |
|
|
|
3,350 |
|
Operating profit |
|
|
(718 |
) |
|
|
(1,038 |
) |
|
|
1,677 |
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
161 |
|
|
|
4 |
|
|
|
4 |
|
Interest expense |
|
|
32 |
|
|
|
3 |
|
|
|
20 |
|
Profit before tax |
|
|
(589 |
) |
|
|
(1,037 |
) |
|
|
1,661 |
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
(176 |
) |
|
|
18 |
|
|
|
387 |
|
Net Profit |
|
|
(413 |
) |
|
|
(1,055 |
) |
|
|
1,274 |
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income |
|
|
(413 |
) |
|
|
(1,055 |
) |
|
|
1,272 |
|
|
|
|
|
|
|
|
|
|
|
Attributable to non-controlling interests |
|
|
(202 |
) |
|
|
(295 |
) |
|
|
3 |
|
Dividends paid to non-controlling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
| Summarized Financial Position |
The tables below show the summarized financial position as at December 31, 2021:
|
|
|
|
|
|
|
|
|
(EUR thousand) |
|
Ompi of Japan
Co., Ltd. |
|
|
Medical Glass a.s. |
|
|
|
|
|
|
|
|
Property, plant and equipment and other non-current assets |
|
|
534 |
|
|
|
13,658 |
|
Net working capital |
|
|
(280 |
) |
|
|
5,582 |
|
Total non-current liabilities and provision |
|
|
— |
|
|
|
(653 |
) |
Net capital employed |
|
|
254 |
|
|
|
18,587 |
|
Net financial position* |
|
|
(1,233 |
) |
|
|
6,204 |
|
Total equity |
|
|
(979 |
) |
|
|
24,791 |
|
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
Equity holders of parent |
|
|
(500 |
) |
|
|
24,727 |
|
Non-controlling interest |
|
|
(479 |
) |
|
|
64 |
|
*Net financial position is determined as the algebraic sum of cash and cash equivalent, other current financial assets, non-current financial liabilities and current financial liabilities
The tables below show the summarized financial position as at December 31, 2020:
|
|
|
|
|
|
|
|
|
(EUR thousand) |
|
Ompi of Japan
Co., Ltd. |
|
|
Medical Glass a.s. |
|
|
|
|
|
|
|
|
Property, plant and equipment and other non-current assets |
|
|
530 |
|
|
|
12,477 |
|
Net working capital |
|
|
(628 |
) |
|
|
7,101 |
|
Total non-current liabilities and provision |
|
|
— |
|
|
|
(596 |
) |
Net capital employed |
|
|
(98 |
) |
|
|
18,982 |
|
Net financial position* |
|
|
(742 |
) |
|
|
2,711 |
|
Total equity |
|
|
(840 |
) |
|
|
21,693 |
|
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
Equity holders of parent |
|
|
(429 |
) |
|
|
21,637 |
|
Non-controlling interest |
|
|
(411 |
) |
|
|
56 |
|
*Net financial position is determined as the algebraic sum of cash and cash equivalent, other current financial assets, non-current financial liabilities and current financial liabilities
|